Agensys
Pioneering advanced treatments for cancer with innovative therapeutic antibodies and drug conjugates.
General Information
Get notified when Agensys moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Agensys
Get real-time alerts for funding, hiring, news, and 40+ signal types.
Start Tracking — FreeDiscover More
Biotechnology
About Agensys
Taxonomy: cancer treatment, therapeutic antibodies, monoclonal antibodies, drug conjugates, oncology research, tumor targeting, prostate cancer, pancreatic cancer, bladder cancer, Santa Monica, Astellas Pharma, biopharmaceutical, innovation
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series D | •••••• | 10 |
|
12 Jul 2007 |
| Debt Financing | •••••• | - | 05 Mar 2003 | |
| Series C | •••••• | - | 04 Mar 2002 | |
| Series B | •••••• | - | 11 Oct 1999 | |
| Series A | •••••• | - | 10 Nov 1997 |
Agensys Alternatives & Competitors
Immunotherapeutics against disease-specific targets
"Powering the Leading-Edge of Biotherapeutics"
Your Trusted Partner for Cutting-Edge Antibody, mRNA-LNP Solutions, and Immunotherapy Breakthroughs.
FAQ About Agensys
Don't just browse. Track.
Signal Tracker monitors Agensys and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.